Telix Pharmaceuticals Q1 2024 revenue up 18% to $114.9M, driven by Illuccix® prostate cancer imaging product.
Telix Pharmaceuticals reports Q1 2024 revenue of US$114.9M, up 18% from the previous quarter, driven by Illuccix®, its prostate cancer imaging product. U.S. revenue increased by 18% to US$111.8M. Telix's CEO, Dr. Christian Behrenbruch, cites the company's precision diagnostics business growth as evidence of an effective market strategy, with the revenue growth providing early funding for late-stage therapeutic programs.
April 17, 2024
4 Articles